Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Ad Wars Over Health Care Overhaul Heat Up
"The ad wars over the health care campaign are heating up once [again] this week," The New York Times reports. At a speech on Monday, Michael Steele, chairman of the Republican National Committee, released a party television ad "which its spokeswoman says will first be broadcast in Arkansas, North Dakota and Nevada." The ad "opens with a tiny infant, and spools out with a narrator"s voice saying: "They"ve loaned Barack Obama their future, without even knowing it. Trillions for rushed government bailouts and takeovers, banks, the auto industry." And then it continues, as children appear on the screen: "The biggest spending spree in our nation"s in history. And they"ll have to pay. The next big ticket item? A risky experiment with our health care. Barack Obama"s massive spending experiment hasn"t healed our economy. His new experiment risks their future and our health.""
generic viagra online
Auburn Pharmacy School Helps Design High-Tech Home Health Pharmacy
A new Auburn University-designed, high-tech pharmacy in Meridian, Miss., is the first of its kind and is a model facility that could be built in communities across the United States.
News of the day
BioTech Medics Announces SHBAN Antiviral Solution Undergoing H1N1 (Swine) Influenza Efficacy Testing
BioTech Medics, Inc. (PINKSHEETS: BMCS) announces that it has contracted to start conducting independent clinical testing of its patented SHBAN™ Antiviral Hand Sanitizer Solution to prove it kills the H1N1 (Swine) Influenza A virus in compliance with FDA and EPA standards.
Endocrinology

DxS' TheraScreen(R) K-RAS Companion Diagnostic Approved For Use With Amgen's Vectibix™ In Canada

DxS, a personalised medicine company, has had its TheraScreen: K-RAS Mutation Kit granted a licence by the regulatory body Health Canada for use as a diagnostic for anti-EGFR therapies and as the companion diagnostic for Amgen"s colorectal cancer therapy, Vectibix™ (panitumumab). The availability of the TheraScreen: K-RAS Mutation Kit will allow colorectal cancer patients in Canada to be screened using the DxS diagnostic to assess their suitability for treatment with Vectibix™. Studies have shown that patients with the non-mutated K-RAS gene may respond to treatment with Vectibix™. Approximately 60 per cent of metastatic colorectal cancer patients have a non-mutated K-RAS gene. Colorectal cancer is the third-leading cause of cancer death in Canada, with around 22,000 diagnosed each year, causing 9,100 deaths1. Dr. Kenneth Pritzker, Mount Sinai Services, Toronto, one of the leading centres carrying out K-RAS testing in Canada said "This is extremely good news that we now have a registered method for K-RAS testing. The DxS K-RAS test is simple to use, highly sensitive and is the companion diagnostic test of choice for assessing a patient"s response to Vectibix™." The approval of the TheraScreen: K-RAS Mutation Kit is a step forward in making personalised medicine more readily available to physicians and patients in Canada. The future of cancer treatment will be guided by the use of technological advances such as these, which enable physicians to better manage a patient"s disease or predisposition towards a disease. Now physicians can choose a treatment approach that is likely to work best in the context of a patient"s genetic and environmental profile. Following the global distribution agreement signed in 2008, Roche Diagnostics will be distributing and supporting sales of the TheraScreen: K-RAS Mutation Kit in Canada beginning in August of this year. About colorectal cancer This year an estimated 22,000 Canadians will be diagnosed with colorectal cancer and 9,100 will die from it. On average, 413 Canadians will be diagnosed with colorectal cancer every week and 171 will die from the disease weekly. One in 14 men is expected to develop colorectal cancer during his lifetime and one in 27 will die from it. One in 16 women is expected to develop colorectal cancer during her lifetime and one in 31 will die from it. Overall, colorectal cancer is the third-leading cause of cancer death in Canada. 1 Data from the Colorectal Association of Canada, http://www.colorectal-cancer.ca DxS


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009